Currently, ARS Pharmaceuticals Inc [SPRY] is trading at $1590000.0, up 1337732%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SPRY shares have gain 9.72% over the last week, with a monthly amount glided 10.26%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ARS Pharmaceuticals Inc [NASDAQ: SPRY] stock has seen the most recent analyst activity on March 07, 2025, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $30. Previously, Oppenheimer started tracking the stock with Outperform rating on February 10, 2025, and set its price target to $40. On August 20, 2024, Cantor Fitzgerald initiated with a Overweight rating. Raymond James upgraded its rating to a Strong Buy and increased its price target to $22 on August 13, 2024. Leerink Partners reiterated its recommendation of a Outperform and raised its price target to $20 on August 12, 2024. Raymond James started tracking with a Outperform rating for this stock on July 25, 2024, and assigned it a price target of $18. In a note dated March 05, 2024, Leerink Partners upgraded an Outperform rating on this stock and boosted its target price from $6 to $18.
This stock has fluctuated between a low of $7.55 and a high of $18.51 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $23.33 within the next 12 months. ARS Pharmaceuticals Inc [NASDAQ: SPRY] shares were valued at $1590000.0 at the most recent close of the market. An investor can expect a potential drop of -100.0% based on the average SPRY price forecast.
Analyzing the SPRY fundamentals
Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -0.28%, Pretax Profit Margin comes in at -0.16%, and Net Profit Margin reading is -0.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.07 and Total Capital is -0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for ARS Pharmaceuticals Inc [NASDAQ:SPRY] is 11.00. Further, the Quick Ratio stands at 10.74, while the Cash Ratio is 1.44. Considering the valuation of this stock, the price to sales ratio is 15.98, the price to book ratio is 6.77.
Transactions by insiders
Recent insider trading involved Karas Eric, Chief Commercial Officer, that happened on Jun 18 ’25 when 15000.0 shares were sold. Officer, ERIC KARAS completed a deal on Jun 18 ’25 to buy 15000.0 shares. Meanwhile, Chief Legal Officer Fitzpatrick Alexander A sold 0.1 million shares on May 20 ’25.
